JP2014519813A - 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用 - Google Patents
癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用 Download PDFInfo
- Publication number
- JP2014519813A JP2014519813A JP2014508515A JP2014508515A JP2014519813A JP 2014519813 A JP2014519813 A JP 2014519813A JP 2014508515 A JP2014508515 A JP 2014508515A JP 2014508515 A JP2014508515 A JP 2014508515A JP 2014519813 A JP2014519813 A JP 2014519813A
- Authority
- JP
- Japan
- Prior art keywords
- gene
- emtgs
- tumor
- kinase inhibitor
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004547 gene signature Effects 0.000 title claims abstract description 45
- 102100023345 Tyrosine-protein kinase ITK/TSK Human genes 0.000 title claims abstract 32
- 238000011282 treatment Methods 0.000 title claims description 51
- 238000007876 drug discovery Methods 0.000 title description 3
- 239000003560 cancer drug Substances 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 249
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 238
- 238000000034 method Methods 0.000 claims abstract description 206
- 229940043355 kinase inhibitor Drugs 0.000 claims abstract description 97
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims abstract description 97
- 201000011510 cancer Diseases 0.000 claims abstract description 86
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims abstract 5
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims abstract 5
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims abstract 5
- 108090000623 proteins and genes Proteins 0.000 claims description 335
- 230000007705 epithelial mesenchymal transition Effects 0.000 claims description 220
- 230000014509 gene expression Effects 0.000 claims description 125
- 210000004027 cell Anatomy 0.000 claims description 119
- 239000000523 sample Substances 0.000 claims description 107
- 150000001875 compounds Chemical class 0.000 claims description 75
- 238000004422 calculation algorithm Methods 0.000 claims description 74
- 229940121647 egfr inhibitor Drugs 0.000 claims description 62
- -1 SPARC Proteins 0.000 claims description 51
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 47
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 46
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 45
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 45
- 101001086785 Homo sapiens Occludin Proteins 0.000 claims description 43
- 102100032604 Occludin Human genes 0.000 claims description 43
- 229960001433 erlotinib Drugs 0.000 claims description 43
- 102100038423 Claudin-3 Human genes 0.000 claims description 41
- 101000882908 Homo sapiens Claudin-3 Proteins 0.000 claims description 41
- 102100037242 Amiloride-sensitive sodium channel subunit alpha Human genes 0.000 claims description 40
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 claims description 40
- 101000740448 Homo sapiens Amiloride-sensitive sodium channel subunit alpha Proteins 0.000 claims description 40
- 239000003112 inhibitor Substances 0.000 claims description 40
- 102100035079 ETS-related transcription factor Elf-3 Human genes 0.000 claims description 39
- 101000877379 Homo sapiens ETS-related transcription factor Elf-3 Proteins 0.000 claims description 39
- 101000995204 Homo sapiens Neurabin-1 Proteins 0.000 claims description 39
- 101000694030 Homo sapiens Periplakin Proteins 0.000 claims description 39
- 101001120469 Legionella pneumophila Peptidoglycan-associated lipoprotein Proteins 0.000 claims description 39
- 102100034438 Neurabin-1 Human genes 0.000 claims description 39
- 102100027184 Periplakin Human genes 0.000 claims description 39
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 claims description 38
- 101001067174 Homo sapiens Plexin-B1 Proteins 0.000 claims description 38
- 102100030417 Matrilysin Human genes 0.000 claims description 38
- 102100034384 Plexin-B1 Human genes 0.000 claims description 38
- 239000003795 chemical substances by application Substances 0.000 claims description 38
- 102100034531 AP-1 complex subunit mu-2 Human genes 0.000 claims description 37
- 102100031936 Anterior gradient protein 2 homolog Human genes 0.000 claims description 37
- 102100029844 B box and SPRY domain-containing protein Human genes 0.000 claims description 37
- 102100038447 Claudin-4 Human genes 0.000 claims description 37
- 102100032460 Ensconsin Human genes 0.000 claims description 37
- 101000924636 Homo sapiens AP-1 complex subunit mu-2 Proteins 0.000 claims description 37
- 101000775021 Homo sapiens Anterior gradient protein 2 homolog Proteins 0.000 claims description 37
- 101000864323 Homo sapiens B box and SPRY domain-containing protein Proteins 0.000 claims description 37
- 101000882890 Homo sapiens Claudin-4 Proteins 0.000 claims description 37
- 101001016782 Homo sapiens Ensconsin Proteins 0.000 claims description 37
- 102100035071 Vimentin Human genes 0.000 claims description 37
- 102100028798 Homeodomain-only protein Human genes 0.000 claims description 36
- 101000839095 Homo sapiens Homeodomain-only protein Proteins 0.000 claims description 36
- 101000969770 Homo sapiens Myelin protein zero-like protein 2 Proteins 0.000 claims description 36
- 102100021272 Myelin protein zero-like protein 2 Human genes 0.000 claims description 36
- 102100033824 A-kinase anchor protein 12 Human genes 0.000 claims description 35
- 101000779382 Homo sapiens A-kinase anchor protein 12 Proteins 0.000 claims description 35
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims description 35
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 35
- 102100039577 ETS translocation variant 5 Human genes 0.000 claims description 34
- 101000813745 Homo sapiens ETS translocation variant 5 Proteins 0.000 claims description 34
- 101000986265 Homo sapiens Protein MTSS 1 Proteins 0.000 claims description 34
- 102100028951 Protein MTSS 1 Human genes 0.000 claims description 34
- 102100032025 ETS homologous factor Human genes 0.000 claims description 33
- 101000921245 Homo sapiens ETS homologous factor Proteins 0.000 claims description 33
- 101000666295 Homo sapiens X-box-binding protein 1 Proteins 0.000 claims description 33
- 102100038151 X-box-binding protein 1 Human genes 0.000 claims description 33
- 102100039244 ETS-related transcription factor Elf-5 Human genes 0.000 claims description 32
- 101000813141 Homo sapiens ETS-related transcription factor Elf-5 Proteins 0.000 claims description 32
- 101000967192 Homo sapiens Metastasis-associated protein MTA3 Proteins 0.000 claims description 32
- 102100040617 Metastasis-associated protein MTA3 Human genes 0.000 claims description 32
- 102100036537 von Willebrand factor Human genes 0.000 claims description 32
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims description 31
- 101000654564 Homo sapiens SH3 domain-containing YSC84-like protein 1 Proteins 0.000 claims description 31
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 claims description 31
- 102100025096 Mesothelin Human genes 0.000 claims description 31
- 102100032637 SH3 domain-containing YSC84-like protein 1 Human genes 0.000 claims description 31
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 claims description 31
- 101150045640 VWF gene Proteins 0.000 claims description 31
- 102100022027 Cytochrome P450 4X1 Human genes 0.000 claims description 30
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 claims description 30
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 claims description 30
- 101800000026 Dentin sialoprotein Proteins 0.000 claims description 30
- 102100038199 Desmoplakin Human genes 0.000 claims description 30
- 102000003815 Interleukin-11 Human genes 0.000 claims description 30
- 108090000177 Interleukin-11 Proteins 0.000 claims description 30
- 108091006525 SLC27A2 Proteins 0.000 claims description 30
- 102100023048 Very long-chain acyl-CoA synthetase Human genes 0.000 claims description 30
- 108010026647 cytochrome P-450 4X1 Proteins 0.000 claims description 30
- 108010075348 Activated-Leukocyte Cell Adhesion Molecule Proteins 0.000 claims description 29
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 claims description 29
- 102100034163 Alpha-actinin-1 Human genes 0.000 claims description 29
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 29
- 102100024210 CD166 antigen Human genes 0.000 claims description 29
- 102100036364 Cadherin-2 Human genes 0.000 claims description 29
- 102100033592 Calponin-3 Human genes 0.000 claims description 29
- 102100036179 Centrosomal protein of 170 kDa Human genes 0.000 claims description 29
- 101710142011 Centrosomal protein of 170 kDa Proteins 0.000 claims description 29
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 claims description 29
- 101000799406 Homo sapiens Alpha-actinin-1 Proteins 0.000 claims description 29
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 claims description 29
- 101000714537 Homo sapiens Cadherin-2 Proteins 0.000 claims description 29
- 101000945410 Homo sapiens Calponin-3 Proteins 0.000 claims description 29
- 101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 claims description 29
- 101000893530 Homo sapiens Leucine-rich repeat transmembrane protein FLRT3 Proteins 0.000 claims description 29
- 101001116302 Homo sapiens Platelet endothelial cell adhesion molecule Proteins 0.000 claims description 29
- 101000864743 Homo sapiens Secreted frizzled-related protein 1 Proteins 0.000 claims description 29
- 101000964419 Homo sapiens Zinc finger and BTB domain-containing protein 10 Proteins 0.000 claims description 29
- 102100026214 Indian hedgehog protein Human genes 0.000 claims description 29
- 101710139099 Indian hedgehog protein Proteins 0.000 claims description 29
- 102100022710 Insulin-like growth factor-binding protein 2 Human genes 0.000 claims description 29
- 108090001007 Interleukin-8 Proteins 0.000 claims description 29
- 102000004890 Interleukin-8 Human genes 0.000 claims description 29
- 102100040900 Leucine-rich repeat transmembrane protein FLRT3 Human genes 0.000 claims description 29
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 29
- 102100030058 Secreted frizzled-related protein 1 Human genes 0.000 claims description 29
- 102100040327 Zinc finger and BTB domain-containing protein 10 Human genes 0.000 claims description 29
- 101001043772 Homo sapiens Inhibitor of nuclear factor kappa-B kinase-interacting protein Proteins 0.000 claims description 28
- 101000931462 Homo sapiens Protein FosB Proteins 0.000 claims description 28
- 101000712982 Homo sapiens Ras association domain-containing protein 8 Proteins 0.000 claims description 28
- 108091058560 IL8 Proteins 0.000 claims description 28
- 102100021595 Inhibitor of nuclear factor kappa-B kinase-interacting protein Human genes 0.000 claims description 28
- 102100020847 Protein FosB Human genes 0.000 claims description 28
- 102100033218 Ras association domain-containing protein 8 Human genes 0.000 claims description 28
- 102100034577 Desmoglein-3 Human genes 0.000 claims description 27
- 101000924311 Homo sapiens Desmoglein-3 Proteins 0.000 claims description 27
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 claims description 27
- 101001008568 Homo sapiens Laminin subunit beta-1 Proteins 0.000 claims description 27
- 101000711466 Homo sapiens SAM pointed domain-containing Ets transcription factor Proteins 0.000 claims description 27
- 101000803403 Homo sapiens Vimentin Proteins 0.000 claims description 27
- 101000785626 Homo sapiens Zinc finger E-box-binding homeobox 1 Proteins 0.000 claims description 27
- 102100032999 Integrin beta-3 Human genes 0.000 claims description 27
- 102000003810 Interleukin-18 Human genes 0.000 claims description 27
- 108090000171 Interleukin-18 Proteins 0.000 claims description 27
- 102100027448 Laminin subunit beta-1 Human genes 0.000 claims description 27
- 102100034018 SAM pointed domain-containing Ets transcription factor Human genes 0.000 claims description 27
- 102100026457 Zinc finger E-box-binding homeobox 1 Human genes 0.000 claims description 27
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 claims description 27
- 102100021084 Forkhead box protein C1 Human genes 0.000 claims description 26
- 101000818310 Homo sapiens Forkhead box protein C1 Proteins 0.000 claims description 26
- 101000994369 Homo sapiens Integrin alpha-5 Proteins 0.000 claims description 26
- 101000760337 Homo sapiens Urokinase plasminogen activator surface receptor Proteins 0.000 claims description 26
- 102100032817 Integrin alpha-5 Human genes 0.000 claims description 26
- 102100024689 Urokinase plasminogen activator surface receptor Human genes 0.000 claims description 26
- 108090000123 Fos-related antigen 1 Proteins 0.000 claims description 25
- 102000003817 Fos-related antigen 1 Human genes 0.000 claims description 25
- 102100039928 Gamma-interferon-inducible protein 16 Human genes 0.000 claims description 25
- 101000960209 Homo sapiens Gamma-interferon-inducible protein 16 Proteins 0.000 claims description 25
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 claims description 25
- 101000612139 Homo sapiens Procollagen C-endopeptidase enhancer 2 Proteins 0.000 claims description 25
- 102100035405 Neutrophil gelatinase-associated lipocalin Human genes 0.000 claims description 25
- 102100041027 Procollagen C-endopeptidase enhancer 2 Human genes 0.000 claims description 25
- 108091002437 YBX1 Proteins 0.000 claims description 25
- 102000033021 YBX1 Human genes 0.000 claims description 25
- 101000785517 Homo sapiens Tight junction protein ZO-3 Proteins 0.000 claims description 24
- 101000723833 Homo sapiens Zinc finger E-box-binding homeobox 2 Proteins 0.000 claims description 24
- 102000004889 Interleukin-6 Human genes 0.000 claims description 24
- 108090001005 Interleukin-6 Proteins 0.000 claims description 24
- 102100026640 Tight junction protein ZO-3 Human genes 0.000 claims description 24
- 102100028458 Zinc finger E-box-binding homeobox 2 Human genes 0.000 claims description 24
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 23
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims description 23
- 102100032074 Transmembrane protein 125 Human genes 0.000 claims description 23
- 102100022556 Glycerol-3-phosphate dehydrogenase 1-like protein Human genes 0.000 claims description 22
- 108700039143 HMGA2 Proteins 0.000 claims description 22
- 102100028999 High mobility group protein HMGI-C Human genes 0.000 claims description 22
- 101150073387 Hmga2 gene Proteins 0.000 claims description 22
- 101000900194 Homo sapiens Glycerol-3-phosphate dehydrogenase 1-like protein Proteins 0.000 claims description 22
- 101000637932 Homo sapiens Transmembrane protein 125 Proteins 0.000 claims description 22
- 101000633054 Homo sapiens Zinc finger protein SNAI2 Proteins 0.000 claims description 22
- 101150058731 STAT5A gene Proteins 0.000 claims description 22
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 claims description 22
- 102100029570 Zinc finger protein SNAI2 Human genes 0.000 claims description 22
- 101000831862 Homo sapiens Transmembrane protein 45B Proteins 0.000 claims description 21
- 101000860430 Homo sapiens Versican core protein Proteins 0.000 claims description 21
- 102100024181 Transmembrane protein 45B Human genes 0.000 claims description 21
- 102100028437 Versican core protein Human genes 0.000 claims description 21
- 238000012360 testing method Methods 0.000 claims description 21
- 102100023721 Ephrin-B2 Human genes 0.000 claims description 20
- 101001049392 Homo sapiens Ephrin-B2 Proteins 0.000 claims description 20
- 101000702691 Homo sapiens Zinc finger protein SNAI1 Proteins 0.000 claims description 20
- 102100030917 Zinc finger protein SNAI1 Human genes 0.000 claims description 20
- 101000609261 Homo sapiens Plasminogen activator inhibitor 2 Proteins 0.000 claims description 19
- 102100039419 Plasminogen activator inhibitor 2 Human genes 0.000 claims description 19
- 208000026310 Breast neoplasm Diseases 0.000 claims description 18
- 102100030608 Mothers against decapentaplegic homolog 7 Human genes 0.000 claims description 18
- 101700026522 SMAD7 Proteins 0.000 claims description 18
- 108010029625 T-Box Domain Protein 2 Proteins 0.000 claims description 18
- 102100038721 T-box transcription factor TBX2 Human genes 0.000 claims description 18
- 102100040834 FXYD domain-containing ion transport regulator 5 Human genes 0.000 claims description 17
- 102100029009 High mobility group protein HMG-I/HMG-Y Human genes 0.000 claims description 17
- 101000893718 Homo sapiens FXYD domain-containing ion transport regulator 5 Proteins 0.000 claims description 17
- 101000986380 Homo sapiens High mobility group protein HMG-I/HMG-Y Proteins 0.000 claims description 17
- 101000880098 Homo sapiens Sushi repeat-containing protein SRPX Proteins 0.000 claims description 17
- 102100037352 Sushi repeat-containing protein SRPX Human genes 0.000 claims description 17
- 230000005764 inhibitory process Effects 0.000 claims description 16
- 206010009944 Colon cancer Diseases 0.000 claims description 15
- 230000004614 tumor growth Effects 0.000 claims description 15
- 206010006187 Breast cancer Diseases 0.000 claims description 14
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 14
- 108010083162 Twist-Related Protein 1 Proteins 0.000 claims description 14
- 102100030398 Twist-related protein 1 Human genes 0.000 claims description 14
- 229950001762 linsitinib Drugs 0.000 claims description 14
- PKCDDUHJAFVJJB-VLZXCDOPSA-N linsitinib Chemical compound C1[C@](C)(O)C[C@@H]1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2C=CC=CC=2)=C2N1C=CN=C2N PKCDDUHJAFVJJB-VLZXCDOPSA-N 0.000 claims description 14
- 102000005962 receptors Human genes 0.000 claims description 14
- 108020003175 receptors Proteins 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 206010027476 Metastases Diseases 0.000 claims description 12
- 108090000630 Oncostatin M Proteins 0.000 claims description 12
- 230000008901 benefit Effects 0.000 claims description 12
- 230000009401 metastasis Effects 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 10
- 230000002596 correlated effect Effects 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 9
- 230000003252 repetitive effect Effects 0.000 claims description 8
- 230000004043 responsiveness Effects 0.000 claims description 8
- 238000000018 DNA microarray Methods 0.000 claims description 7
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 claims description 7
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 108091008743 testicular receptors 4 Proteins 0.000 claims description 7
- 230000007246 mechanism Effects 0.000 claims description 6
- 108010063961 serpin-2 Proteins 0.000 claims description 6
- 102100021888 Helix-loop-helix protein 1 Human genes 0.000 claims description 5
- 101000897691 Homo sapiens Helix-loop-helix protein 1 Proteins 0.000 claims description 5
- 238000001574 biopsy Methods 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims description 4
- 102000028416 insulin-like growth factor binding Human genes 0.000 claims description 4
- 108091022911 insulin-like growth factor binding Proteins 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 claims description 3
- 108090000353 Histone deacetylase Proteins 0.000 claims description 3
- 102000003964 Histone deacetylase Human genes 0.000 claims description 3
- 108091005735 TGF-beta receptors Proteins 0.000 claims description 3
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- 102100036409 Activated CDC42 kinase 1 Human genes 0.000 claims description 2
- 101100174793 Arabidopsis thaliana GA20OX1 gene Proteins 0.000 claims description 2
- 101000928956 Homo sapiens Activated CDC42 kinase 1 Proteins 0.000 claims description 2
- 101000987310 Homo sapiens Serine/threonine-protein kinase PAK 2 Proteins 0.000 claims description 2
- 101000802109 Homo sapiens Transducin-like enhancer protein 3 Proteins 0.000 claims description 2
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 claims description 2
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 claims description 2
- 229940125895 MET kinase inhibitor Drugs 0.000 claims description 2
- 101700056750 PAK1 Proteins 0.000 claims description 2
- 102100027910 Serine/threonine-protein kinase PAK 1 Human genes 0.000 claims description 2
- 102100027939 Serine/threonine-protein kinase PAK 2 Human genes 0.000 claims description 2
- 102100034698 Transducin-like enhancer protein 3 Human genes 0.000 claims description 2
- 230000004156 Wnt signaling pathway Effects 0.000 claims description 2
- 230000007321 biological mechanism Effects 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 102000038594 Cdh1/Fizzy-related Human genes 0.000 claims 13
- 101150108706 FOS1 gene Proteins 0.000 claims 8
- 101710181917 Serine proteinase inhibitor 1 Proteins 0.000 claims 5
- 101001001462 Homo sapiens Importin subunit alpha-5 Proteins 0.000 claims 4
- 102100035692 Importin subunit alpha-1 Human genes 0.000 claims 4
- 101150007959 Lum gene Proteins 0.000 claims 4
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims 2
- 102100025304 Integrin beta-1 Human genes 0.000 claims 2
- 210000000601 blood cell Anatomy 0.000 claims 2
- 101710161231 Pectate lyase 1 Proteins 0.000 claims 1
- 101710162447 Pectin lyase A Proteins 0.000 claims 1
- 101710179615 Probable pectin lyase A Proteins 0.000 claims 1
- 108091006524 SLC27A3 Proteins 0.000 claims 1
- 102000001332 SRC Human genes 0.000 claims 1
- 108060006706 SRC Proteins 0.000 claims 1
- 102100023047 Solute carrier family 27 member 3 Human genes 0.000 claims 1
- 101150078133 aur gene Proteins 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000008410 smoothened signaling pathway Effects 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 abstract description 5
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 79
- 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 description 79
- 102000001301 EGF receptor Human genes 0.000 description 53
- 108060006698 EGF receptor Proteins 0.000 description 50
- 101150015144 88 gene Proteins 0.000 description 33
- 230000035945 sensitivity Effects 0.000 description 28
- 102100025805 Cadherin-1 Human genes 0.000 description 27
- 230000000694 effects Effects 0.000 description 25
- 238000000338 in vitro Methods 0.000 description 20
- 239000003446 ligand Substances 0.000 description 19
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 18
- 229960003722 doxycycline Drugs 0.000 description 18
- 102000000905 Cadherin Human genes 0.000 description 17
- 108050007957 Cadherin Proteins 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 230000006698 induction Effects 0.000 description 15
- 230000004044 response Effects 0.000 description 15
- 241000237858 Gastropoda Species 0.000 description 14
- 230000008859 change Effects 0.000 description 14
- 230000012010 growth Effects 0.000 description 14
- 230000035755 proliferation Effects 0.000 description 14
- 239000000090 biomarker Substances 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108020004459 Small interfering RNA Proteins 0.000 description 12
- 230000004913 activation Effects 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 12
- 230000037361 pathway Effects 0.000 description 12
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 12
- 102000004140 Oncostatin M Human genes 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 10
- 108010065472 Vimentin Proteins 0.000 description 10
- 101150074545 Zeb1 gene Proteins 0.000 description 10
- 239000002246 antineoplastic agent Substances 0.000 description 10
- 210000000481 breast Anatomy 0.000 description 10
- 238000009826 distribution Methods 0.000 description 10
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 210000005048 vimentin Anatomy 0.000 description 10
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 9
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 9
- 229960002584 gefitinib Drugs 0.000 description 9
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 8
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 210000000496 pancreas Anatomy 0.000 description 8
- 239000013615 primer Substances 0.000 description 8
- 230000002062 proliferating effect Effects 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 102000003746 Insulin Receptor Human genes 0.000 description 7
- 108010001127 Insulin Receptor Proteins 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 210000001072 colon Anatomy 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 230000004565 tumor cell growth Effects 0.000 description 7
- 102000003693 Hedgehog Proteins Human genes 0.000 description 6
- 108090000031 Hedgehog Proteins Proteins 0.000 description 6
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 6
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- 208000037841 lung tumor Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000013211 curve analysis Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 238000002493 microarray Methods 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 229940120982 tarceva Drugs 0.000 description 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- 239000012830 cancer therapeutic Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 230000004660 morphological change Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 3
- 206010055113 Breast cancer metastatic Diseases 0.000 description 3
- 102100041002 Forkhead box protein H1 Human genes 0.000 description 3
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 3
- 101000892840 Homo sapiens Forkhead box protein H1 Proteins 0.000 description 3
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 3
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 3
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 101700032040 SMAD1 Proteins 0.000 description 3
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004709 cell invasion Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000010219 correlation analysis Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000009509 drug development Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 230000036732 histological change Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical class C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 2
- HESLKTSGTIBHJU-UHFFFAOYSA-N 6-[[4-[(3-methylsulfonylphenyl)methylamino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3,4-dihydro-1H-quinolin-2-one Chemical compound CS(=O)(=O)C1=CC=CC(CNC=2C(=CN=C(NC=3C=C4CCC(=O)NC4=CC=3)N=2)C(F)(F)F)=C1 HESLKTSGTIBHJU-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 102100030708 GTPase KRas Human genes 0.000 description 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- CDMGBJANTYXAIV-UHFFFAOYSA-N SB 203580 Chemical compound C1=CC(S(=O)C)=CC=C1C1=NC(C=2C=CC(F)=CC=2)=C(C=2C=CN=CC=2)N1 CDMGBJANTYXAIV-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 102000013814 Wnt Human genes 0.000 description 2
- 108050003627 Wnt Proteins 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000009522 phase III clinical trial Methods 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 239000003909 protein kinase inhibitor Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- XGRLSUFHELJJAB-JGSYTFBMSA-M sodium;[(2r)-2-hydroxy-3-[(z)-octadec-9-enoyl]oxypropyl] hydrogen phosphate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)([O-])=O XGRLSUFHELJJAB-JGSYTFBMSA-M 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 1
- IGUBBWJDMLCRIK-UHFFFAOYSA-N 2-[[2-(2-methoxy-4-morpholin-4-ylanilino)-5-(trifluoromethyl)pyridin-4-yl]amino]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1NC1=CC(NC=2C(=CC(=CC=2)N2CCOCC2)OC)=NC=C1C(F)(F)F IGUBBWJDMLCRIK-UHFFFAOYSA-N 0.000 description 1
- UYJNQQDJUOUFQJ-UHFFFAOYSA-N 2-[[5-chloro-2-[2-methoxy-4-(4-morpholinyl)anilino]-4-pyrimidinyl]amino]-N-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(=CC=2)N2CCOCC2)OC)=NC=C1Cl UYJNQQDJUOUFQJ-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 101150008021 80 gene Proteins 0.000 description 1
- 101150102613 91 gene Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 101150018445 Axl gene Proteins 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 description 1
- 108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102000007590 Calpain Human genes 0.000 description 1
- 108010032088 Calpain Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100022404 E3 ubiquitin-protein ligase Midline-1 Human genes 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 229940124783 FAK inhibitor Drugs 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 101710181403 Frizzled Proteins 0.000 description 1
- 102000005698 Frizzled receptors Human genes 0.000 description 1
- 108010045438 Frizzled receptors Proteins 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 101000680670 Homo sapiens E3 ubiquitin-protein ligase Midline-1 Proteins 0.000 description 1
- 101001077604 Homo sapiens Insulin receptor substrate 1 Proteins 0.000 description 1
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 description 1
- 101001039199 Homo sapiens Low-density lipoprotein receptor-related protein 6 Proteins 0.000 description 1
- 101000891845 Homo sapiens Protein FAM3C Proteins 0.000 description 1
- 101000802356 Homo sapiens Tight junction protein ZO-1 Proteins 0.000 description 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
- 108010031792 IGF Type 2 Receptor Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 1
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 1
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 description 1
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 description 1
- 102100040704 Low-density lipoprotein receptor-related protein 6 Human genes 0.000 description 1
- 102000019218 Mannose-6-phosphate receptors Human genes 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 1
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 1
- 101100365690 Mus musculus Shc1 gene Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010058765 Oncogene Protein pp60(v-src) Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- OYONTEXKYJZFHA-SSHUPFPWSA-N PHA-665752 Chemical compound CC=1C(C(=O)N2[C@H](CCC2)CN2CCCC2)=C(C)NC=1\C=C(C1=C2)/C(=O)NC1=CC=C2S(=O)(=O)CC1=C(Cl)C=CC=C1Cl OYONTEXKYJZFHA-SSHUPFPWSA-N 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 108010069873 Patched Receptors Proteins 0.000 description 1
- 102000000017 Patched Receptors Human genes 0.000 description 1
- 102000012850 Patched-1 Receptor Human genes 0.000 description 1
- 108010065129 Patched-1 Receptor Proteins 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100040823 Protein FAM3C Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 101100291026 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MGA2 gene Proteins 0.000 description 1
- 101100190847 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PMP3 gene Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102000004584 Somatomedin Receptors Human genes 0.000 description 1
- 108010017622 Somatomedin Receptors Proteins 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102100034686 Tight junction protein ZO-1 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- XHXFZZNHDVTMLI-UHFFFAOYSA-N dasatinib monohydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl XHXFZZNHDVTMLI-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000002782 epithelial mesenchymal cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 108700021358 erbB-1 Genes Proteins 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000000370 laser capture micro-dissection Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- MTSNDBYBIZSILH-UHFFFAOYSA-N n-phenylquinazolin-4-amine Chemical compound N=1C=NC2=CC=CC=C2C=1NC1=CC=CC=C1 MTSNDBYBIZSILH-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000025402 neoplasm of esophagus Diseases 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 231100001221 nontumorigenic Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 description 1
- 229950009919 saracatinib Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 101150012554 shc gene Proteins 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229950005976 tivantinib Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229940124629 β-receptor antagonist Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161517789P | 2011-04-25 | 2011-04-25 | |
| US61/517,789 | 2011-04-25 | ||
| US201261632894P | 2012-01-31 | 2012-01-31 | |
| US61/632,894 | 2012-01-31 | ||
| PCT/US2012/034989 WO2012149014A1 (en) | 2011-04-25 | 2012-04-25 | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016248712A Division JP2017113000A (ja) | 2011-04-25 | 2016-12-22 | 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014519813A true JP2014519813A (ja) | 2014-08-21 |
| JP2014519813A5 JP2014519813A5 (cg-RX-API-DMAC10.html) | 2015-05-21 |
Family
ID=46201785
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508515A Pending JP2014519813A (ja) | 2011-04-25 | 2012-04-25 | 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用 |
| JP2016248712A Pending JP2017113000A (ja) | 2011-04-25 | 2016-12-22 | 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016248712A Pending JP2017113000A (ja) | 2011-04-25 | 2016-12-22 | 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9896730B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2702173A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2014519813A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2012149014A1 (cg-RX-API-DMAC10.html) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2013146993A1 (ja) * | 2012-03-28 | 2015-12-14 | 株式会社オンチップ・バイオテクノロジーズ | 末梢循環腫瘍細胞単位の悪性度の検出方法及びそのキット |
| JP2022522428A (ja) * | 2019-02-27 | 2022-04-19 | オックスフォード ユニヴァーシティ イノヴェーション リミテッド | 高悪性度漿液性卵巣癌（ｈｇｓｏｃ） |
| JP2024521104A (ja) * | 2021-05-21 | 2024-05-28 | ウニベルシテ カソリーク デ ルーベン | ミトコンドリア標的化抗酸化剤に対する癌の応答性を評価するための分子署名 |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8491927B2 (en) * | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| JP2013532489A (ja) * | 2010-08-02 | 2013-08-19 | ザ ブロード インスティテュート， インコーポレイテッド | 遺伝子発現プロファイリングに基づくがん治療への応答の予測ならびにモニタリング |
| US11507548B1 (en) * | 2011-09-21 | 2022-11-22 | Amazon Technologies, Inc. | System and method for generating a classification model with a cost function having different penalties for false positives and false negatives |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| EP2971179B1 (en) | 2013-03-14 | 2019-01-09 | Mayo Foundation for Medical Education and Research | Detecting neoplasm |
| ES2651522T3 (es) * | 2013-12-16 | 2018-01-26 | Humanitas Mirasole S.P.A. | Altos niveles de FT de TEM para el diagnóstico del cáncer, en particular de cáncer colorrectal (CCR) y de páncreas (CP) |
| KR101583673B1 (ko) | 2014-02-28 | 2016-01-08 | 이화여자대학교 산학협력단 | 난소암 환자의 항암제 치료 반응성 예측을 위한 마커 dlx5 |
| KR101601943B1 (ko) | 2014-02-28 | 2016-03-09 | 이화여자대학교 산학협력단 | 난소암 환자의 항암제 치료 반응성 예측을 위한 마커 uchl1 |
| KR101601942B1 (ko) | 2014-02-28 | 2016-03-09 | 이화여자대학교 산학협력단 | 난소암 환자의 항암제 치료 반응성 예측을 위한 마커 tet1 |
| KR101601941B1 (ko) | 2014-02-28 | 2016-03-09 | 이화여자대학교 산학협력단 | 난소암 환자의 항암제 치료 반응성 예측을 위한 마커 mta3 |
| BR112016022056B1 (pt) | 2014-03-26 | 2023-04-11 | Astex Therapeutics Limited | Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico |
| US10736900B2 (en) * | 2014-03-26 | 2020-08-11 | Astex Therapeutics Ltd | Combinations of an FGFR inhibitor and an IGF1R inhibitor |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| WO2015144854A1 (en) * | 2014-03-26 | 2015-10-01 | Servizo Galego De Saúde (Sergas) | Method for predicting patient outcome and therapy response in metastatic colorectal cancer |
| JP6462437B2 (ja) * | 2014-05-08 | 2019-01-30 | 花王株式会社 | 皮膚の乾燥状態の評価方法 |
| US10184154B2 (en) | 2014-09-26 | 2019-01-22 | Mayo Foundation For Medical Education And Research | Detecting cholangiocarcinoma |
| TWI719960B (zh) | 2015-02-10 | 2021-03-01 | 英商阿斯迪克治療公司 | 新穎組成物 |
| WO2016160454A1 (en) | 2015-03-27 | 2016-10-06 | Exact Sciences Corporation | Detecting esophageal disorders |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| GB201512133D0 (en) | 2015-07-10 | 2015-08-19 | Bergenbio As | Biomarkers |
| JP6871926B2 (ja) | 2015-08-31 | 2021-05-19 | マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ ａｎｄ Ｒｅｓｅａｒｃｈ | 胃の新生物を検出すること |
| HUE050567T2 (hu) | 2015-09-23 | 2020-12-28 | Janssen Pharmaceutica Nv | Triciklusos heterociklusok rák kezelésére |
| WO2017050865A1 (en) | 2015-09-23 | 2017-03-30 | Janssen Pharmaceutica Nv | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
| CN106996975B (zh) * | 2016-01-22 | 2019-05-31 | 益善生物技术股份有限公司 | 循环肿瘤细胞蛋白分型试剂盒 |
| CN107475358A (zh) * | 2016-06-08 | 2017-12-15 | 益善生物技术股份有限公司 | 结直肠癌组织溯源ctc分型鉴定试剂盒 |
| CN107475354A (zh) * | 2016-06-08 | 2017-12-15 | 益善生物技术股份有限公司 | 前列腺癌组织溯源ctc分型鉴定试剂盒 |
| CN107475353A (zh) * | 2016-06-08 | 2017-12-15 | 益善生物技术股份有限公司 | 肺癌组织溯源ctc分型鉴定试剂盒 |
| CN110520543A (zh) * | 2017-03-29 | 2019-11-29 | 中美冠科生物技术（太仓）有限公司 | 确定胃癌对西妥昔单抗敏感性的系统和方法 |
| CN110662844A (zh) * | 2017-05-22 | 2020-01-07 | 内盖夫生物技术国家研究所有限公司 | 用于肺癌的诊断的生物标志物 |
| JP7044518B2 (ja) | 2017-11-10 | 2022-03-30 | オリンパス株式会社 | 細胞集塊の突起形成能評価方法 |
| CN113498440B (zh) * | 2019-02-22 | 2025-05-30 | 国立大学法人东北大学 | 新型胰腺癌上皮间质转化标记物 |
| KR20210003502A (ko) * | 2019-07-02 | 2021-01-12 | 연세대학교 산학협력단 | 암의 예방, 개선 또는 치료용 조성물 |
| CN110283889B (zh) * | 2019-07-22 | 2020-10-13 | 中南大学 | 一种双基因监控反应体系、试剂盒及其应用 |
| ES3073708T3 (en) * | 2020-04-09 | 2026-07-14 | THESTRA Oy | Eplin as a biomarker for cancer |
| CN116710479A (zh) | 2020-09-14 | 2023-09-05 | 赛罗斯生物科技 | Sh3yl1抗体、包含其的组合物及其载体和用途 |
| WO2022099221A1 (en) * | 2020-11-09 | 2022-05-12 | Johnson Heather H | Compositions and methods for cancer diagnosis, prognosis and management |
| WO2022150447A1 (en) * | 2021-01-06 | 2022-07-14 | Washington University | Partial-emt signature for prediction of high-risk histopathologic features and cancer outcomes across demographic populations |
| CN121023021A (zh) * | 2025-08-29 | 2025-11-28 | 湖北医药学院 | 一种基于emt异质性的肿瘤分子分型方法及其在癌症进化可视化中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090286850A1 (en) * | 2008-03-07 | 2009-11-19 | Shaaban Salam A | Inhibition of EMT induction in tumor cells by anti-cancer agents |
| JP2011501660A (ja) * | 2007-10-03 | 2011-01-13 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | インスリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌反応を予測する生物学的マーカー |
Family Cites Families (370)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4503035B1 (en) | 1978-11-24 | 1996-03-19 | Hoffmann La Roche | Protein purification process and product |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US5231176A (en) | 1984-08-27 | 1993-07-27 | Genentech, Inc. | Distinct family DNA encoding of human leukocyte interferons |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4868103A (en) | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
| AU7180787A (en) | 1986-04-22 | 1987-10-29 | Salk Institute For Biological Studies, The | Fibroblast growth factor |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| US5468468A (en) | 1989-02-09 | 1995-11-21 | The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Method for making a monoclonal antibody, monoclonal antibodies to α PD |
| US5252725A (en) | 1989-06-23 | 1993-10-12 | The Trustees Of The University Of Pennsylvania | α-1-antichymotrypsin, analogues and methods of production |
| US5668264A (en) | 1990-06-11 | 1997-09-16 | Nexstar Pharmaceuticals, Inc. | High affinity PDGF nucleic acid ligands |
| US5674685A (en) | 1990-06-11 | 1997-10-07 | Nexstar Pharmaceuticals, Inc. | High affinity PDGF nucleic acid ligands |
| US5023264A (en) | 1990-07-16 | 1991-06-11 | American Home Products Corporation | Rapamycin oximes |
| US5120726A (en) | 1991-03-08 | 1992-06-09 | American Home Products Corporation | Rapamycin hydrazones |
| US5023263A (en) | 1990-08-09 | 1991-06-11 | American Home Products Corporation | 42-oxorapamycin |
| US5023262A (en) | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
| US5358944A (en) | 1990-09-19 | 1994-10-25 | American Home Products Corporation | Rapamycin esters for treating transplantation rejection |
| US5130307A (en) | 1990-09-28 | 1992-07-14 | American Home Products Corporation | Aminoesters of rapamycin |
| US5378696A (en) | 1990-09-19 | 1995-01-03 | American Home Products Corporation | Rapamycin esters |
| US5221670A (en) | 1990-09-19 | 1993-06-22 | American Home Products Corporation | Rapamycin esters |
| US5233036A (en) | 1990-10-16 | 1993-08-03 | American Home Products Corporation | Rapamycin alkoxyesters |
| JPH06503966A (ja) | 1990-12-21 | 1994-05-12 | クリエイティブ バイオモレキュルズ インコーポレイテッド | 生合成したｐｄｇｆアンタゴニスト |
| EP0584082B1 (en) | 1991-01-31 | 2000-05-31 | Cor Therapeutics, Inc. | Domains of extracellular region of human platelet derived growth factor receptor polypeptides |
| GB9106678D0 (en) | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
| US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
| US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
| US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5194447A (en) | 1992-02-18 | 1993-03-16 | American Home Products Corporation | Sulfonylcarbamates of rapamycin |
| US5138051A (en) | 1991-08-07 | 1992-08-11 | American Home Products Corporation | Rapamycin analogs as immunosuppressants and antifungals |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| DE69222637T2 (de) | 1991-05-10 | 1998-02-26 | Rhone Poulenc Rorer Int | Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase |
| US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
| US5120725A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Bicyclic rapamycins |
| US5120727A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Rapamycin dimers |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| US5169851A (en) | 1991-08-07 | 1992-12-08 | American Home Products Corporation | Rapamycin analog as immunosuppressants and antifungals |
| US5202332A (en) | 1991-08-07 | 1993-04-13 | American Home Products Corporation | Rapamycin analog as immunosuppressant |
| US5162333A (en) | 1991-09-11 | 1992-11-10 | American Home Products Corporation | Aminodiesters of rapamycin |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
| US5164399A (en) | 1991-11-18 | 1992-11-17 | American Home Products Corporation | Rapamycin pyrazoles |
| US5817310A (en) | 1991-12-02 | 1998-10-06 | Cor Therapeutics, Inc. | Inhibitory immunoglobulin polypeptides to human PDGF beta receptor |
| US5238950A (en) | 1991-12-17 | 1993-08-24 | Schering Corporation | Inhibitors of platelet-derived growth factor |
| US5221740A (en) | 1992-01-16 | 1993-06-22 | American Home Products Corporation | Oxepane isomers of rapamycin useful as immunosuppressive agents |
| EP0552108B1 (en) | 1992-01-17 | 1999-11-10 | Lakowicz, Joseph R. | Energy transfer phase-modulation fluoro-immunoassay |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5262424A (en) | 1992-02-18 | 1993-11-16 | American Home Products Corporation | Composition of sulfonylcarbamates of rapamycin and method of treating diseases requiring immunosuppression therewith |
| US5260299A (en) | 1992-03-05 | 1993-11-09 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-Carboalkoxy)Sulfamates Useful as Immunosuppressive Agents |
| US5177203A (en) | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
| TW225528B (cg-RX-API-DMAC10.html) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| US5821234A (en) | 1992-09-10 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of proliferation of vascular smooth muscle cell |
| US5869462A (en) | 1992-09-10 | 1999-02-09 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of proliferation of vascular smooth muscle cell |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5411967A (en) | 1992-10-13 | 1995-05-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5489680A (en) | 1992-10-13 | 1996-02-06 | American Home Products Corporation | Carbamates of rapamycin |
| US5434260A (en) | 1992-10-13 | 1995-07-18 | American Home Products Corporation | Carbamates of rapamycin |
| US5480988A (en) | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5302584A (en) | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
| US5480989A (en) | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5262423A (en) | 1992-10-29 | 1993-11-16 | American Home Products Corporation | Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5260300A (en) | 1992-11-19 | 1993-11-09 | American Home Products Corporation | Rapamycin carbonate esters as immuno-suppressant agents |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5620687A (en) | 1993-02-25 | 1997-04-15 | Zymogenetics, Inc. | Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors |
| US5976534A (en) | 1993-02-25 | 1999-11-02 | Zymogenetics, Inc. | Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin |
| AU693475B2 (en) | 1993-10-01 | 1998-07-02 | Novartis Ag | Pyrimidineamine derivatives and processes for the preparation thereof |
| US5378836A (en) | 1993-10-08 | 1995-01-03 | American Home Products Corporation | Rapamycin oximes and hydrazones |
| US5391730A (en) | 1993-10-08 | 1995-02-21 | American Home Products Corporation | Phosphorylcarbamates of rapamycin and oxime derivatives thereof |
| US5373014A (en) | 1993-10-08 | 1994-12-13 | American Home Products Corporation | Rapamycin oximes |
| US5952304A (en) | 1993-10-22 | 1999-09-14 | Trigen Limited | Platelet-derived growth factor analogues |
| US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| JPH07133280A (ja) | 1993-11-09 | 1995-05-23 | Takeda Chem Ind Ltd | セフェム化合物、その製造法および抗菌組成物 |
| US5385910A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Gem-distributed esters of rapamycin |
| US5385909A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Heterocyclic esters of rapamycin |
| US5385908A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
| BR9408323A (pt) | 1993-12-17 | 1997-08-19 | Sandoz Ag | Derivados de rapamicina |
| US5389639A (en) | 1993-12-29 | 1995-02-14 | American Home Products Company | Amino alkanoic esters of rapamycin |
| US6384192B1 (en) | 1993-12-30 | 2002-05-07 | President & Fellows Of Harvard College | Vertebrate embryonic pattern-inducing proteins |
| US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5504291A (en) | 1994-02-14 | 1996-04-02 | Square D Company | Contact blade assembly for a circuit breaker |
| WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| US5525610A (en) | 1994-03-31 | 1996-06-11 | American Home Products Corporation | 42-Epi-rapamycin and pharmaceutical compositions thereof |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| ES2109796T3 (es) | 1994-05-03 | 1998-01-16 | Ciba Geigy Ag | Derivados de pirrolopirimidilo con efecto antiproliferante. |
| US5463048A (en) | 1994-06-14 | 1995-10-31 | American Home Products Corporation | Rapamycin amidino carbamates |
| US5958942A (en) | 1994-07-15 | 1999-09-28 | Takeda Chemical Industries, Ltd. | Tricyclic nitrogen ring compounds, their production and use |
| CA2156767A1 (en) | 1994-08-25 | 1996-02-26 | Kenichi Matsunaga | Binding agent for growth factor |
| US5476851A (en) | 1994-09-08 | 1995-12-19 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase |
| US5795910A (en) | 1994-10-28 | 1998-08-18 | Cor Therapeutics, Inc. | Method and compositions for inhibiting protein kinases |
| US5491231A (en) | 1994-11-28 | 1996-02-13 | American Home Products Corporation | Hindered N-oxide esters of rapamycin |
| US5563145A (en) | 1994-12-07 | 1996-10-08 | American Home Products Corporation | Rapamycin 42-oximes and hydroxylamines |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
| JP4249804B2 (ja) | 1995-04-03 | 2009-04-08 | ノバルティス・アクチエンゲゼルシャフト | ピラゾール誘導体およびその製造法 |
| CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| US5723594A (en) | 1995-06-07 | 1998-03-03 | Nexstar Pharmaceuticals, Inc. | High affinity PDGF nucleic acid ligands |
| ES2276405T3 (es) | 1995-06-02 | 2007-06-16 | Gilead Sciences, Inc. | Ligandos de oligonucleotidos de alta afinidad a pdgf. |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US5618837A (en) | 1995-06-07 | 1997-04-08 | Zymogenetics, Inc. | PDGF antagonists III |
| US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
| US6229002B1 (en) | 1995-06-07 | 2001-05-08 | Nexstar Pharmaceuticlas, Inc. | Platelet derived growth factor (PDGF) nucleic acid ligand complexes |
| DE69624921T2 (de) | 1995-06-09 | 2003-09-11 | Novartis Ag, Basel | Rapamycinderivate |
| DE69632402T2 (de) | 1995-06-30 | 2005-05-19 | Zymogenetics, Inc., Seattle | 4-(2-(n-(-2-carboxamidoindole)aminiethyl)-benzensulfonamide oder sulfonylharnstoffe als pdgf antagoniste |
| PL188959B1 (pl) | 1995-07-06 | 2005-05-31 | Novartis Ag | Pirolopirymidyny i sposoby ich wytwarzania |
| DK9500262U4 (da) | 1995-07-07 | 1996-10-07 | Bonus Energy As | Bundramme til vindmøllehus samt vindmølle omfattende samme |
| FR2736550B1 (fr) | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
| EP0857210B1 (en) | 1995-10-23 | 2003-09-03 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DK0780386T3 (da) | 1995-12-20 | 2003-02-03 | Hoffmann La Roche | Matrixmetalloproteaseinhibitorer |
| US5780462A (en) | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
| US6140317A (en) | 1996-01-23 | 2000-10-31 | Novartis Ag | Pyrrolopyrimidines and processes for their preparation |
| JP3406763B2 (ja) | 1996-01-30 | 2003-05-12 | 東レ・ダウコーニング・シリコーン株式会社 | シリコーンゴム組成物 |
| CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GB9603097D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| DE19629652A1 (de) | 1996-03-06 | 1998-01-29 | Thomae Gmbh Dr K | 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE19608588A1 (de) | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| EP0929694A4 (en) | 1996-03-15 | 2002-05-02 | Penn State Res Found | DETECTION OF TUMOR-RELATED EXTRACELLULAR NUCLEIC ACID USING PLASMA OR BLOOD SERUM USING NUCLEIC ACID AMPLIFICATION TESTS |
| DE59710417D1 (de) | 1996-03-15 | 2003-08-14 | Novartis Ag | N-7 HETEROCYCLYL-PYRROLO[ 2,3-d]PYRIMIDINE UND IHRE VERWENDUNG |
| US5882644A (en) | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
| CN100503580C (zh) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
| GB9607729D0 (en) | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
| BR9709959A (pt) | 1996-06-24 | 2000-05-09 | Pfizer | Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas |
| BR9709974A (pt) | 1996-06-27 | 1999-08-10 | Pfizer | Derivados de 2-(2-oxo-etidileno)-imidazolidin-4-ona e seu uso como inibidores da transferase da proteina de farnesila |
| CA2259157A1 (en) | 1996-07-05 | 1998-01-15 | Mount Sinai Hospital Corporation | Oligomerized receptors which affect pathways regulated by transmembrane ligands for elk-related receptor tyrosine kinases |
| WO1998002441A2 (en) | 1996-07-12 | 1998-01-22 | Ariad Pharmaceuticals, Inc. | Non immunosuppressive antifungal rapalogs |
| US6171779B1 (en) | 1996-07-12 | 2001-01-09 | University Of Medicine & Dentistry Of New Jersey | HMGI proteins in cancer |
| EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| AR007855A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen |
| US6391874B1 (en) | 1996-07-13 | 2002-05-21 | Smithkline Beecham Corporation | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| EP0923585B1 (en) | 1996-07-18 | 2002-05-08 | Pfizer Inc. | Phosphinate based inhibitors of matrix metalloproteases |
| EP0922030A1 (en) | 1996-08-23 | 1999-06-16 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
| PT938486E (pt) | 1996-08-23 | 2008-03-27 | Novartis Ag | Pirrolopirimidinas substituídas e processos para a sua preparação |
| US5922730A (en) | 1996-09-09 | 1999-07-13 | American Home Products Corporation | Alkylated rapamycin derivatives |
| AU719392B2 (en) | 1996-10-01 | 2000-05-11 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compounds |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| WO1998014449A1 (en) | 1996-10-02 | 1998-04-09 | Novartis Ag | Fused pyrazole derivatives and processes for their preparation |
| CA2266519C (en) | 1996-10-02 | 2007-01-23 | Novartis Ag | Pyrimidine derivatives and processes for the preparation thereof |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| GB9621757D0 (en) | 1996-10-18 | 1996-12-11 | Ciba Geigy Ag | Phenyl-substituted bicyclic heterocyclyl derivatives and their use |
| US6077864A (en) | 1997-01-06 | 2000-06-20 | Pfizer Inc. | Cyclic sulfone derivatives |
| HUP0000852A2 (hu) | 1997-02-03 | 2001-05-28 | Pfizer Products Inc. | Aril-szulfonil-amino-hidroxámsav-származékok, valamint e vegyületeket tartalmazó gyógyászati készítmények |
| ES2301194T3 (es) | 1997-02-05 | 2008-06-16 | Warner-Lambert Company Llc | Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular. |
| US5945422A (en) | 1997-02-05 | 1999-08-31 | Warner-Lambert Company | N-oxides of amino containing pyrido 2,3-D! pyrimidines |
| JP2000507975A (ja) | 1997-02-07 | 2000-06-27 | ファイザー・インク | Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用 |
| NZ336836A (en) | 1997-02-11 | 2001-02-23 | Pfizer | Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments |
| CA2289102A1 (en) | 1997-05-07 | 1998-11-12 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| US6251628B1 (en) | 1997-05-20 | 2001-06-26 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules encoding Smad7 |
| US6180632B1 (en) | 1997-05-28 | 2001-01-30 | Aventis Pharmaceuticals Products Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| US6245760B1 (en) | 1997-05-28 | 2001-06-12 | Aventis Pharmaceuticals Products, Inc | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| US6159978A (en) | 1997-05-28 | 2000-12-12 | Aventis Pharmaceuticals Product, Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| CA2291709A1 (en) | 1997-05-30 | 1998-12-03 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| WO1999007701A1 (en) | 1997-08-05 | 1999-02-18 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
| TR200000368T2 (tr) | 1997-08-08 | 2000-07-21 | Pfizer Products Inc. | Ariloksiariarilsülfonilamino hidroksamik asit türevleri. |
| DE69838172T2 (de) | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
| US6015815A (en) | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
| AU744939B2 (en) | 1997-09-26 | 2002-03-07 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| TW557297B (en) | 1997-09-26 | 2003-10-11 | Abbott Lab | Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same |
| SK6652000A3 (en) | 1997-11-11 | 2002-05-09 | Pfizer Prod Inc | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| US5932580A (en) | 1997-12-01 | 1999-08-03 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | PDGF receptor kinase inhibitory compounds their preparation and compositions |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| JPH11236333A (ja) | 1997-12-30 | 1999-08-31 | Pfizer Prod Inc | 抗ガン剤として有用なイミダゾリン−４−オン誘導体 |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| AU4079999A (en) | 1998-05-15 | 1999-12-06 | Imclone Systems Incorporated | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
| KR100743287B1 (ko) | 1998-05-29 | 2007-07-26 | 수젠, 인크. | 피롤기로 치환된 2-인돌리논 단백질 인산화 효소 억제제 |
| UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| US7342108B2 (en) | 1998-06-25 | 2008-03-11 | The General Hospital Corporation | De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof |
| US7368551B2 (en) | 1998-06-25 | 2008-05-06 | The General Hospital Corporation | De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof |
| US6566131B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad6 expression |
| US6015809A (en) | 1998-08-17 | 2000-01-18 | American Home Products Corporation | Photocyclized rapamycin |
| CA2341739C (en) | 1998-08-27 | 2005-07-12 | Pfizer Products Inc. | Quinolin-2-one derivatives useful as anticancer agents |
| KR20010072991A (ko) | 1998-08-27 | 2001-07-31 | 실버스타인 아써 에이. | 항암제로서 유용한 알키닐-치환된 퀴놀린-2-온 유도체 |
| AU5914299A (en) | 1998-09-11 | 2000-04-03 | Eli Lilly And Company | Antagonists of fibroblast growth factor |
| US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
| NZ510588A (en) | 1998-09-18 | 2003-08-29 | Abbott Gmbh & Co | Pyrrolopyrimidines as protein kinase inhibitors |
| EP1004578B1 (en) | 1998-11-05 | 2004-02-25 | Pfizer Products Inc. | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
| EP1006113A1 (en) | 1998-12-02 | 2000-06-07 | Pfizer Products Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth |
| US6107091A (en) | 1998-12-03 | 2000-08-22 | Isis Pharmaceuticals Inc. | Antisense inhibition of G-alpha-16 expression |
| US5981732A (en) | 1998-12-04 | 1999-11-09 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-13 expression |
| WO2000035455A1 (en) | 1998-12-15 | 2000-06-22 | Telik, Inc. | Heteroaryl-aryl ureas as igf-1 receptor antagonists |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| WO2000046380A2 (en) | 1999-02-08 | 2000-08-10 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
| TR200201296T2 (tr) | 1999-02-11 | 2002-07-22 | Pfizer Products Inc. | Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri |
| US6586447B1 (en) | 1999-04-01 | 2003-07-01 | Pfizer Inc | 3,3-disubstituted-oxindole derivatives useful as anticancer agents |
| US6046321A (en) | 1999-04-09 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-i1 expression |
| IL144977A0 (en) | 1999-05-21 | 2002-06-30 | Bristol Myers Squibb Co | Pyrrolotriazine derivatives and pharmaceutical compositions containing the same |
| ES2161655B1 (es) | 1999-07-01 | 2002-06-01 | Consejo Superior Investigacion | Procedimiento para determinar la capacidad invasiva y metastasica de un tumor epitelial mediante el uso de snail. |
| US6455525B1 (en) | 1999-11-04 | 2002-09-24 | Cephalon, Inc. | Heterocyclic substituted pyrazolones |
| US6358954B1 (en) | 1999-11-09 | 2002-03-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
| UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| ES2212971T3 (es) | 1999-11-30 | 2004-08-16 | Pfizer Products Inc. | Derivados de quinolina utiles para la inhibicion de la farnesil protein transferasa. |
| US6448086B1 (en) | 2000-01-18 | 2002-09-10 | Diagnostic Systems Laboratories, Inc. | Insulin-like growth factor system and cancer |
| HN2000000266A (es) | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. |
| WO2001068912A2 (en) | 2000-03-15 | 2001-09-20 | Epigenomics Ag | Diagnosis of diseases associated with tumor suppressor genes and oncogenes |
| JP2003526367A (ja) | 2000-03-16 | 2003-09-09 | ジェネティカ インコーポレイテッド | Ｒｎａ干渉の方法とｒｎａ干渉組成物 |
| AU2001252940A1 (en) | 2000-03-22 | 2001-10-03 | Amgen Inc. | Fibroblast growth factor receptor-like molecules and uses thereof |
| TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| AU2000240570A1 (en) | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
| US6365354B1 (en) | 2000-07-31 | 2002-04-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of lysophospholipase I expression |
| JP2004519422A (ja) | 2000-08-04 | 2004-07-02 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | ２−（４−ピリジル）アミノ−６−ジアルコキシフェニルピリド〔２，３−ｄ〕ピリミジン−７−オン |
| US6566135B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 6 expression |
| US20020169562A1 (en) | 2001-01-29 | 2002-11-14 | Gregory Stephanopoulos | Defining biological states and related genes, proteins and patterns |
| TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
| US20030053995A1 (en) | 2001-06-15 | 2003-03-20 | Mien-Chie Hung | Methods and compositions for inhibiting EGF receptor activity |
| SE0102168D0 (sv) | 2001-06-19 | 2001-06-19 | Karolinska Innovations Ab | New use and new compounds |
| IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| FR2828601B1 (fr) | 2001-08-10 | 2003-11-07 | Iroc Technologies | Ensemble de circuits electroniques comportant des moyens de decontamination de parties contaminees par des erreurs |
| US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
| US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
| CN100391958C (zh) | 2001-09-19 | 2008-06-04 | 安万特医药股份有限公司 | 化合物 |
| JP2005512962A (ja) | 2001-09-20 | 2005-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 抗ｐｄｇｆ抗体および設計抗体の産生方法 |
| WO2003035619A1 (en) | 2001-10-25 | 2003-05-01 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| AU2002348393A1 (en) | 2001-10-25 | 2003-05-06 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
| AU2002348394A1 (en) | 2001-10-25 | 2003-05-06 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
| WO2003035616A2 (en) | 2001-10-25 | 2003-05-01 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US20070237770A1 (en) | 2001-11-30 | 2007-10-11 | Albert Lai | Novel compositions and methods in cancer |
| SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
| AU2002358279A1 (en) | 2001-12-21 | 2003-07-30 | Arcturus Engineering, Inc. | Biomarkers for breast cancer |
| US20030144260A1 (en) | 2002-01-03 | 2003-07-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Heterocyclic compounds, method of developing new drug leads and combinatorial libraries used in such method |
| JP2005532036A (ja) | 2002-01-09 | 2005-10-27 | 理化学研究所 | 癌プロフィール |
| US7553485B2 (en) | 2002-01-18 | 2009-06-30 | Pierre Fabre Medicament | Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof |
| US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| AU2003209340A1 (en) | 2002-01-18 | 2003-09-02 | Bristol-Myers Squibb Company | Predictor sets for tyrosine kinase pathways |
| EP1476192B1 (en) | 2002-02-14 | 2007-04-25 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for treating hyperproliferative conditions |
| US7081340B2 (en) | 2002-03-13 | 2006-07-25 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| AU2003233576A1 (en) | 2002-05-17 | 2003-12-02 | Sugen, Inc. | Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals |
| MXPA04011624A (es) | 2002-05-24 | 2005-03-07 | Schering Corp | Anticuerpo neutralizante humano anti-igfr. |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| SI1509230T1 (sl) | 2002-06-05 | 2007-06-30 | Cedars Sinai Medical Center | Gefitinib (iressa) za zdravljenje raka |
| US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| WO2004000102A2 (en) | 2002-06-19 | 2003-12-31 | Abgenix, Inc. | Method for predicting response to epidermal growth factor receptor-directed therapy |
| TW200401638A (en) | 2002-06-20 | 2004-02-01 | Bristol Myers Squibb Co | Heterocyclic inhibitors of kinases |
| GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| WO2004005891A2 (en) | 2002-07-10 | 2004-01-15 | The Regents Of The University Of Michigan | Expression profile of lung cancer |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| AU2003265349A1 (en) | 2002-08-02 | 2004-02-23 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7084270B2 (en) | 2002-08-14 | 2006-08-01 | Hoffman-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| US20040209930A1 (en) | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
| TW200501960A (en) | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
| US7129351B2 (en) | 2002-11-04 | 2006-10-31 | Hoffmann-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| US8008003B2 (en) | 2002-11-15 | 2011-08-30 | Genomic Health, Inc. | Gene expression profiling of EGFR positive cancer |
| PL377620A1 (pl) | 2002-11-18 | 2006-02-06 | F. Hoffmann-La Roche Ag | Diazynopirymidyny |
| AU2003297297A1 (en) | 2002-11-22 | 2004-06-18 | North Shore-Long Island Jewish Research Institute | Elf3 gene compositions and methods |
| AU2003300899A1 (en) | 2002-12-12 | 2004-06-30 | Oncotech, Inc. | Genes related to sensitivity and resistance to chemotherapeutic drug treatment |
| TWI299664B (en) | 2003-01-06 | 2008-08-11 | Osi Pharm Inc | (2-carboxamido)(3-amino)thiophene compounds |
| US7696225B2 (en) | 2003-01-06 | 2010-04-13 | Osi Pharmaceuticals, Inc. | (2-carboxamido)(3-Amino) thiophene compounds |
| EP1597558A2 (en) | 2003-01-08 | 2005-11-23 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
| WO2004065602A1 (es) | 2003-01-17 | 2004-08-05 | Universidad Autónoma de Madrid | Procedimiento para identificar la transición epitelio-mesenquimal de células mesoteliales (temcm) e identificar compuestos moduladores de temcm, composiciones farmacéuticas y su uso en el diagnóstico y tratamiento de enfermedades que cursan con temcm |
| WO2004071572A2 (en) | 2003-02-06 | 2004-08-26 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
| US7253166B2 (en) | 2003-04-22 | 2007-08-07 | Irm Llc | 6-phenyl-7H-pyrrolo[2,3-d]pyrimidine compounds that induce neuronal differentiation in embryonic stem cells |
| JP2007506442A (ja) | 2003-05-30 | 2007-03-22 | ゲノミック ヘルス， インコーポレイテッド | Ｅｇｆｒ阻害薬への応答に関する遺伝子発現マーカー |
| US20060078941A1 (en) | 2003-06-09 | 2006-04-13 | Santin Alessandro D | Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium |
| US20070092881A1 (en) | 2003-07-10 | 2007-04-26 | Central Institute For Experimental Animals | Gene markers of tumor metastasis |
| ES2905579T3 (es) | 2003-07-10 | 2022-04-11 | Genomic Health Inc | Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama |
| AU2004260689B8 (en) | 2003-07-29 | 2008-05-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| EP1664716A4 (en) | 2003-08-15 | 2008-08-13 | Smithkline Beecham Corp | CANCER BIOMARKERS |
| JP4795237B2 (ja) | 2003-08-21 | 2011-10-19 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | Ｎ−置換ピラゾリル−アミジル−ベンズイミダゾリルｃ−Ｋｉｔ阻害剤 |
| AP2006003552A0 (en) | 2003-08-21 | 2006-04-30 | Osi Pharm Inc | N3 - substituted imidazopyridine C-kit inhibitors. |
| BRPI0413746A (pt) | 2003-08-21 | 2006-10-24 | Osi Pharm Inc | composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo |
| EP1980629A3 (en) | 2003-08-28 | 2008-12-17 | Ipsogen | Identification of an erbb2 gene expression signature in breast cancers |
| DE10342503A1 (de) | 2003-09-12 | 2005-04-14 | Merck Patent Gmbh | Benzyl-Benzimidazolylderivate |
| GB0321694D0 (en) | 2003-09-16 | 2003-10-15 | Ark Therapeutics Ltd | Genes and their therapeutic use |
| ES2372694T3 (es) | 2003-10-15 | 2012-01-25 | OSI Pharmaceuticals, LLC | Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina. |
| JP2007509613A (ja) | 2003-10-16 | 2007-04-19 | ジェノミック ヘルス， インコーポレイテッド | 遺伝子発現プロファイリングのためのｑＲＴ−ＰＣＲアッセイシステム |
| AR046639A1 (es) | 2003-11-21 | 2005-12-14 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti- igfr1 |
| DE10356579A1 (de) | 2003-12-04 | 2005-07-07 | Merck Patent Gmbh | Aminderivate |
| JP5192632B2 (ja) | 2003-12-12 | 2013-05-08 | 愛知県 | 肺癌組織中の遺伝子発現強度を識別する方法 |
| WO2005066211A2 (en) | 2003-12-19 | 2005-07-21 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
| EP1759010A4 (en) | 2004-01-07 | 2008-12-24 | Bristol Myers Squibb Co | BIOMARKERS AND METHOD FOR DETERMINING SENSITIVITY AGAINST MODULATORS OF EGF (EPIDERMAL GROWTH FACTOR) RECEPTORS |
| US20080113874A1 (en) | 2004-01-23 | 2008-05-15 | The Regents Of The University Of Colorado | Gefitinib sensitivity-related gene expression and products and methods related thereto |
| US8017321B2 (en) | 2004-01-23 | 2011-09-13 | The Regents Of The University Of Colorado, A Body Corporate | Gefitinib sensitivity-related gene expression and products and methods related thereto |
| JP4848355B2 (ja) | 2004-02-27 | 2011-12-28 | アンスティテュ・キュリ | 臨床診療における新規増殖マーカーおよび癌の予後または診断のためのそれらの用途 |
| JP2007530954A (ja) | 2004-03-26 | 2007-11-01 | ブリストル−マイヤーズ スクイブ カンパニー | 非小細胞肺癌において上皮細胞増殖因子レセプターモジュレーターに対する感受性を決定するためのバイオマーカーおよび方法 |
| US20060019268A1 (en) | 2004-03-26 | 2006-01-26 | Research Development Foundation | Molecular markers of cisplatin resistance in cancer and uses thereof |
| WO2005099363A2 (en) | 2004-03-26 | 2005-10-27 | Whitehead Institute For Biomedical Research | Methods of diagnosing, preventing and treating cancer metastasis |
| MXPA06011423A (es) | 2004-04-02 | 2007-01-23 | Osi Pharm Inc | Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico. |
| US20050256154A1 (en) | 2004-05-04 | 2005-11-17 | Kin-Chun Luk | 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides |
| WO2005107803A2 (en) | 2004-05-06 | 2005-11-17 | Vernalis Plc | Methods of determining the prognosis and treatment of subjects with lung cancer |
| US7741035B2 (en) | 2004-05-21 | 2010-06-22 | Board Of Trustees Of The University Of Arkansas | Use of gene expression profiling to predict survival in cancer patient |
| EP1766086A4 (en) | 2004-05-21 | 2009-10-28 | Univ Arkansas | USE OF GENETIC EXPRESSION PROFILING TO PREVENT THE CHANCE OF SURVIVAL OF A PATIENT WITH CANCER |
| JP5422120B2 (ja) | 2004-05-27 | 2014-02-19 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト | 癌患者による上皮成長因子受容体阻害薬に対する臨床転帰の予測方法 |
| US7102002B2 (en) | 2004-06-16 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| CN101014365B (zh) | 2004-07-16 | 2011-04-13 | 辉瑞产品公司 | 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤 |
| FR2875601B1 (fr) | 2004-09-17 | 2007-04-13 | Genome Express S A Sa | Vimentine phosphorylee comme marqueur de l'agressivite et/ou l'invasivite des tumeurs |
| ES2365858T3 (es) | 2004-10-13 | 2011-10-11 | Merck Patent Gmbh | Derivados de fenilurea como sustancia inhibidora de tirosina-quinasas para el tratamiento de enfermedades tumorales. |
| US7151176B2 (en) | 2004-10-21 | 2006-12-19 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
| CA2584804A1 (en) | 2004-10-21 | 2006-05-04 | The Penn State Research Foundation | Eph receptor tumor biomarkers |
| DE102004054215A1 (de) | 2004-11-10 | 2006-05-11 | Merck Patent Gmbh | Pyridopyrimidinonderivate |
| DE102004054216A1 (de) | 2004-11-10 | 2006-05-11 | Merck Patent Gmbh | Substituierte 4-Amino-pyridopyrimidinone |
| EP2281841A3 (en) | 2004-12-03 | 2013-10-23 | Merck Sharp & Dohme Corp. | Biomarkers for pre-selection of patients for anti-IGF1R therapy |
| US7666595B2 (en) | 2005-02-25 | 2010-02-23 | The Brigham And Women's Hospital, Inc. | Biomarkers for predicting prostate cancer progression |
| DE102005011058A1 (de) | 2005-03-10 | 2006-09-14 | Merck Patent Gmbh | Substituierte Tetrahydro-pyrrolo-chinolinderivate |
| JP2008533053A (ja) | 2005-03-11 | 2008-08-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド | ヒストン脱アセチル化酵素阻害剤は、がん細胞を上皮増殖因子受容体阻害剤に対して感受性にする |
| WO2006101925A2 (en) | 2005-03-16 | 2006-09-28 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| US8383357B2 (en) | 2005-03-16 | 2013-02-26 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| DE102005015253A1 (de) | 2005-04-04 | 2006-10-05 | Merck Patent Gmbh | Pyrazolderivate |
| DE102005017259A1 (de) | 2005-04-14 | 2006-10-19 | Merck Patent Gmbh | Purinderivate |
| US20090061422A1 (en) | 2005-04-19 | 2009-03-05 | Linke Steven P | Diagnostic markers of breast cancer treatment and progression and methods of use thereof |
| KR20080011199A (ko) | 2005-04-19 | 2008-01-31 | 교와 핫꼬 고교 가부시끼가이샤 | 질소 함유 복소환 화합물 |
| WO2006121991A2 (en) | 2005-05-06 | 2006-11-16 | Diadexus, Inc. | Compositions and methods for detection, prognosis and treatment of breast cancer |
| WO2006134989A1 (ja) | 2005-06-15 | 2006-12-21 | Kyowa Hakko Kogyo Co., Ltd. | 含窒素複素環化合物 |
| SI1913157T2 (sl) | 2005-06-28 | 2017-02-28 | Genentech, Inc. | EGFR in KRAS mutacije za napoved bolnikovega odziva na zdravljenje z EGFR inhibitorjem |
| US8133692B2 (en) | 2005-07-20 | 2012-03-13 | University Of South Florida | Methods of predicting responsiveness to chemotherapeutic agents and selecting treatments |
| GB0515026D0 (en) | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
| NZ565511A (en) | 2005-07-22 | 2011-03-31 | Five Prime Therapeutics Inc | Compositions and methods of treating disease with FGFR fusion proteins |
| US20090155786A1 (en) | 2005-08-15 | 2009-06-18 | President And Fellows Of Harvard College | Compositions and methods for detecting markers of cancer |
| AU2005335661A1 (en) | 2005-08-16 | 2007-02-22 | F. Hoffmann-La Roche Ag | Novel 4-amino-thieno[3,2-C]pyridine-7-carboxylic acid amides |
| AU2006287175A1 (en) | 2005-09-01 | 2007-03-08 | Precision Therapeutics, Inc. | Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics |
| AU2006292278B2 (en) | 2005-09-20 | 2012-03-08 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| US20070154916A1 (en) | 2005-11-04 | 2007-07-05 | Johji Inazawa | Method for detecting cancer and a method for suppressing cancer |
| US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| US20070128636A1 (en) | 2005-12-05 | 2007-06-07 | Baker Joffre B | Predictors Of Patient Response To Treatment With EGFR Inhibitors |
| US20080299113A1 (en) | 2005-12-19 | 2008-12-04 | Arnold Lee D | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents |
| JP2007175021A (ja) | 2005-12-28 | 2007-07-12 | Sysmex Corp | 大腸がんのリンパ節転移マーカー |
| WO2008121102A2 (en) | 2006-02-21 | 2008-10-09 | The Regents Of The University Of Michigan | Hedgehog signaling pathway antagonist cancer treatment |
| US20070218512A1 (en) | 2006-02-28 | 2007-09-20 | Alex Strongin | Methods related to mmp26 status as a diagnostic and prognostic tool in cancer management |
| US20070231822A1 (en) | 2006-02-28 | 2007-10-04 | Michael Mitas | Methods for the detection and treatment of cancer |
| JP2009529329A (ja) | 2006-03-09 | 2009-08-20 | トラスティーズ オブ ボストン ユニバーシティ | 鼻腔上皮細胞の遺伝子発現プロファイルを用いた、肺疾患のための診断および予後診断の方法 |
| JP2009532027A (ja) | 2006-03-28 | 2009-09-10 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 抗ｉｇｆ−１ｒ抗体およびその使用 |
| US7812143B2 (en) | 2006-03-31 | 2010-10-12 | Memorial Sloan-Kettering Cancer Center | Biomarkers for cancer treatment |
| AU2007255110B8 (en) | 2006-06-02 | 2014-04-10 | Pfizer Products Inc. | Circulating tumor cell assay |
| US20080026481A1 (en) | 2006-06-16 | 2008-01-31 | Michael Mitas | Molecular based two-marker assays that predict outcome of adenocarcinoma patients |
| WO2008005469A2 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Igfbp2 biomarker |
| US20080167532A1 (en) | 2006-10-13 | 2008-07-10 | Mayo Foundation For Medical Education And Research | Assessing cancer treatment responsiveness |
| US7622456B2 (en) | 2006-11-06 | 2009-11-24 | Non-Profit Organization Chang Gung Memorial Hospital | Method on clinical applications in head neck cancer by using DSG3 molecule for predicting malignant degree of cancer, serving as a molecular target and using RNA jamming sequence on inhibition-specific of DSG3 expression |
| DK2087139T3 (en) | 2006-11-07 | 2017-02-13 | Univ Arkansas | Gene expression profiling-based identification of high-risk multiple myeloma genomic signatures |
| WO2008070460A2 (en) | 2006-11-27 | 2008-06-12 | The Regents Of The University Of California | The use of soluble e-cadherin as a novel serum marker |
| WO2008073290A1 (en) | 2006-12-08 | 2008-06-19 | The Board Of Trustees Of The University Of Arkansas | Tp53 gene expression and uses thereof |
| US7838234B2 (en) | 2007-01-30 | 2010-11-23 | Pharmacyclics, Inc. | Methods for determining cancer resistance to histone deacetylase inhibitors |
| US20100323373A1 (en) | 2007-02-27 | 2010-12-23 | Stefan Evers | Method for the assessment of the inhibitory activity of antibodies against insulin-like growth factor i receptor |
| ES2707551T3 (es) | 2007-03-02 | 2019-04-04 | Amgen Inc | Métodos y composiciones para tratar enfermedades tumorales |
| WO2008115470A2 (en) | 2007-03-16 | 2008-09-25 | East Carolina University | Hox-gene expression as a biomarker for igf-1r therapeutics |
| US8377636B2 (en) | 2007-04-13 | 2013-02-19 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to kinase inhibitors |
| EP2145021A2 (en) | 2007-05-17 | 2010-01-20 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
| WO2009023172A2 (en) | 2007-08-09 | 2009-02-19 | The Johns Hopkins University | Predictions of responsiveness to egfr inhibitors |
| US8622606B2 (en) | 2007-09-25 | 2014-01-07 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Micro-channels, micro-mixers, and micro-reactors |
| AU2008307634A1 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| WO2009049228A2 (en) | 2007-10-10 | 2009-04-16 | The Regents Of The University Of Michigan | Compositions and methods for assessing disorders |
| ES2397672T3 (es) * | 2007-12-05 | 2013-03-08 | The Wistar Institute Of Anatomy And Biology | Método de diagnóstico de cánceres de pulmón utilizando perfiles de expresión genética en células mononucleares de sangre periférica |
| JP2011511005A (ja) | 2008-02-04 | 2011-04-07 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | ２−アミノピリジン系キナーゼ阻害薬 |
| JP2012500631A (ja) | 2008-08-20 | 2012-01-12 | ザ リージェンツ オブ ザ ユニバーシティー オブ コロラド， ア ボディー コーポレイト | Ｉｇｆ−１ｒ処置に対する癌の感受性を評価するためのマーカー |
| WO2010120966A1 (en) | 2009-04-17 | 2010-10-21 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| US20110143960A1 (en) * | 2009-12-10 | 2011-06-16 | Labarbera Daniel V | 3d-models for high-throughput screening drug discovery and development |
| WO2012061510A2 (en) * | 2010-11-03 | 2012-05-10 | Merck Sharp & Dohme Corp. | Methods of predicting cancer cell response to therapeutic agents |
-
2012
- 2012-04-25 JP JP2014508515A patent/JP2014519813A/ja active Pending
- 2012-04-25 US US13/455,972 patent/US9896730B2/en not_active Expired - Fee Related
- 2012-04-25 EP EP12725171.8A patent/EP2702173A1/en not_active Withdrawn
- 2012-04-25 WO PCT/US2012/034989 patent/WO2012149014A1/en not_active Ceased
-
2016
- 2016-12-22 JP JP2016248712A patent/JP2017113000A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011501660A (ja) * | 2007-10-03 | 2011-01-13 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | インスリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌反応を予測する生物学的マーカー |
| US20090286850A1 (en) * | 2008-03-07 | 2009-11-19 | Shaaban Salam A | Inhibition of EMT induction in tumor cells by anti-cancer agents |
Non-Patent Citations (8)
| Title |
|---|
| JPN5014006365; ＢＹＥＲＳ Ｌ: '３７ ＡＮ ＥＰＩＴＨＥＬＩＡＬ ＴＯ ＭＥＳＥＮＣＨＹＭＡＬ ＴＲＡＮＳＩＴＩＯＮ（ＥＭＴ） ＧＥＮＥ ＥＸＰＲＥＳＳＩＯＮ ＳＩＧＮＡＴＵＲＥ ＩＤＥＮＴＩＦＩＥＳ ＡＸＬ 以下備考' ＥＵＲＯＰＥＡＮ ＪＯＵＲＮＡＬ ＯＦ ＣＡＮＣＥＲ，ＳＵＰＰＬＥＭＥＮＴＳ Ｖ８ Ｎ７, 20101101, Ｐ２１, ＰＥＲＧＡＭＯＮ * |
| JPN5014006366; ＬＯＢＯＤＡ ＡＮＤＲＥ: 'ＥＭＴ ＩＳ ＴＨＥ ＤＯＭＩＮＡＮＴ ＰＲＯＧＲＡＭ ＩＮ ＨＵＭＡＮ ＣＯＬＯＮ ＣＡＮＣＥＲ' ＢＭＣ ＭＥＤＩＣＡＬ ＧＥＮＯＭＩＣＳ Ｖ４ Ｎ１, 20110120, Ｐ９, ＢＩＯＭＥＤ ＣＥＮＴＲＡＬ ＬＴＤ． * |
| JPN5014006367; ＫＯＲＮＥＬＩＡ ＰＯＬＹＡＫ: 'ＴＲＡＮＳＩＴＩＯＮＳ ＢＥＴＷＥＥＮ ＥＰＩＴＨＥＬＩＡＬ ＡＮＤ ＭＥＳＥＮＣＨＹＭＡＬ ＳＴＡＴＥＳ： ＡＣＱＵＩＳＩＴＩＯＮ ＯＦ ＭＡＬＩＧＮＡＮＴ ＡＮＤ ＳＴＥＭ ＣＥＬＬ ＴＲＡＩＴＳ' ＮＡＴＵＲＥ ＲＥＶＩＥＷＳ ＣＡＮＣＥＲ Ｖ９ Ｎ４, 20090305, Ｐ２６５-２７３ * |
| JPN5014006368; ＴＯＢＩＡＳ ＪＯＹＣＥ: 'Ａ ＭＯＬＥＣＵＬＡＲ ＳＩＧＮＡＴＵＲＥ ＦＯＲ ＥＰＩＴＨＥＬＩＡＬ ＴＯ ＭＥＳＥＮＣＨＹＭＡＬ ＴＲＡＮＳＩＴＩＯＮ 以下備考' ＣＬＩＮＩＣＡＬ ＆ ＥＸＰＥＲＩＭＥＮＴＡＬ ＭＥＴＡＳＴＡＳＩＳ Ｖ２６ Ｎ６, 20090402, Ｐ５６９-５８７, ＫＬＵＷＥＲ ＡＣＡＤＥＭＩＣ ＰＵＢＬＩＳＨＥＲＳ * |
| JPN5014006369; ＶＯＵＬＧＡＲＩ ＡＮＧＥＬＩＫＩ: 'ＥＰＩＴＨＥＬＩＡＬ-ＭＥＳＥＮＣＨＹＭＡＬ ＴＲＡＮＳＩＴＩＯＮ ＩＮ ＣＡＮＣＥＲ ＭＥＴＡＳＴＡＳＩＳ： 以下備考' ＢＢＡ-ＲＥＶＩＥＷＳ ＯＮ ＣＡＮＣＥＲ Ｖ１７９６ Ｎ２, 20091201, Ｐ７５-９０, ＥＬＳＥＶＩＥＲ ＳＣＩＥＮＣＥ ＢＶ * |
| JPN5014006370; ＴＯＮＹ ＢＬＩＣＫ: 'ＥＰＩＴＨＥＬＩＡＬ ＭＥＳＥＮＣＨＹＭＡＬ ＴＲＡＮＳＩＴＩＯＮ ＴＲＡＩＴＳ ＩＮ ＨＵＭＡＮ ＢＲＥＡＳＴ ＣＡＮＣＥＲ ＣＥＬＬ ＬＩＮＥＳ ＰＡＲＡＬＬＥＬ 以下備考' ＪＯＵＲＮＡＬ ＯＦ ＭＡＭＭＡＲＹ ＧＬＡＮＤ ＢＩＯＬＯＧＹ ＡＮＤ ＮＥＯＰＬＡＳＩＡ Ｖ１５ Ｎ２, 20100604, Ｐ２３５-２５２, ＫＬＵＷＥＲ ＡＣＡＤＥＭＩＣ ＰＵＢＬＩＳＨＥＲＳ-ＰＬＥＮＵＭ ＰＵＢＬＩＳＨＥＲＳ * |
| JPN5014006371; ＳＡＢＢＡＨ ＭＩＣＨＥＬＥ: 'ＭＯＬＥＣＵＬＡＲ ＳＩＧＮＡＴＵＲＥ ＡＮＤ ＴＨＥＲＡＰＥＵＴＩＣ ＰＥＲＳＰＥＣＴＩＶＥ ＯＦ ＴＨＥ ＥＰＩＴＨＥＬＩＡＬ-ＴＯ-ＭＥＳＥＮＣＨＹＭＡＬ 以下備考' ＤＲＵＧ ＲＥＳＩＳＴＡＮＣＥ ＵＰＤＡＴＥＳ Ｖ１１ Ｎ４-５, 20080801, Ｐ１２３-１５１, ＣＨＵＲＣＨＩＬＬ ＬＩＶＩＮＧＳＴＯＮＥ * |
| JPN5014006372; ＪＯＳＥＰＨ Ｈ ＴＡＵＢＥ: 'ＣＯＲＥ ＥＰＩＴＨＥＬＩＡＬ-ＴＯ-ＭＥＳＥＮＣＨＹＭＡＬ ＴＲＡＮＳＩＴＩＯＮ ＩＮＴＥＲＡＣＴＯＭＥ ＧＥＮＥ-ＥＸＰＲＥＳＳＩＯＮ ＳＩＧＮＡＴＵＲＥ 以下備考' ＰＲＯＣＥＥＤＩＮＧＳ ＯＦ ＮＡＴＩＯＮＡＬ ＡＣＡＤＥＭＹ ＯＦ ＳＣＩＥＮＣＥＳ Ｖ１０７ Ｎ３５, 20100831, Ｐ１５４４９-１５４５４, ＮＡＴＩＯＮＡＬ ＡＣＡＤＥＭＹ ＯＦ ＳＣＩＥＮＣＥＳ * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2013146993A1 (ja) * | 2012-03-28 | 2015-12-14 | 株式会社オンチップ・バイオテクノロジーズ | 末梢循環腫瘍細胞単位の悪性度の検出方法及びそのキット |
| JP2022522428A (ja) * | 2019-02-27 | 2022-04-19 | オックスフォード ユニヴァーシティ イノヴェーション リミテッド | 高悪性度漿液性卵巣癌（ｈｇｓｏｃ） |
| JP2024521104A (ja) * | 2021-05-21 | 2024-05-28 | ウニベルシテ カソリーク デ ルーベン | ミトコンドリア標的化抗酸化剤に対する癌の応答性を評価するための分子署名 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017113000A (ja) | 2017-06-29 |
| US9896730B2 (en) | 2018-02-20 |
| EP2702173A1 (en) | 2014-03-05 |
| US20120302572A1 (en) | 2012-11-29 |
| WO2012149014A1 (en) | 2012-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017113000A (ja) | 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用 | |
| JP5055284B2 (ja) | インシュリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー | |
| US20120142028A1 (en) | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors | |
| US8093011B2 (en) | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors | |
| US20110217309A1 (en) | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors | |
| US7998688B2 (en) | Inhibition of EMT induction in tumor cells by anti-cancer agents | |
| JP2011516826A (ja) | 間葉系様腫瘍細胞またはこの形成を阻害する作用剤の同定のための方法 | |
| JP2010540960A (ja) | インスリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌反応を予測する生物学的マーカー | |
| US8465912B2 (en) | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation | |
| JP2012519281A (ja) | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 | |
| US20110275644A1 (en) | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors | |
| US20120214830A1 (en) | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150330 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150330 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160204 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160428 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160704 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160715 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160824 |